Intas Pharma gest CDSCO panel nod to manufacture, market anticancer drug Enzalutamide tablet
New Delhi: Intas Pharma has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to manufacture and market Enzalutamide Tablet 80 mg.
However, this nod is subject to the condition that the firm should conduct a Phase IV clinical trial.
This came after the drug maker Intas pharma presented the proposal for grant of permission to manufacture and market Enzalutamide Tablet 80 mg along with bioequivalence (BE) study reports in fasting and fed conditions.
Intas Pharma has informed that Enzalutamide capsules 80 mg are approved in India (Year 2020), and Enzalutamide tablet 80 mg is also approved in the US (Year 2020) and in Europe (Year 2013).
Enzalutamide is a second-generation androgen receptor inhibitor used to treat castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
Enzalutamide is a competitive androgen receptor (AR) inhibitor that has a threefold inhibition on the androgen signaling pathway without significant AR agonist activity. It inhibits androgen binding to its receptor, androgen receptor nuclear translocation, and subsequent interaction with chromosomal DNA to upregulate oncogenes.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.